Phase 1 Study on Safety and Preliminary Efficacy of CTX112 in Adults with Refractory Systemic Lupus Erythematosus, Systemic Sclerosis, or Idiopathic Inflammatory Myopathy

The primary objective of this Phase 1 study is to evaluate the **safety** and preliminary **efficacy** of CTX112 in adult subjects with refractory autoimmune diseases, specifically active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM). The clinical relevance of this study lies in addressing the unmet medical need for effective treatments in patients with these challenging conditions, who have not responded adequately to existing therapies.

The clinical trial involves a total of **70 participants** diagnosed with active **systemic lupus erythematosus (SLE)**, systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM). The study population includes both male and female subjects, with an age range that spans from adolescents to adults. Participants were selected to ensure a diverse representation of the affected population, including vulnerable groups. The trial does not specify particular lifestyle considerations such as diet or physical activity. The selection process aimed to encompass a broad spectrum of individuals affected by these conditions, without imposing restrictive lifestyle criteria.

The clinical trial is a **Phase 1** study designed to evaluate the safety and preliminary efficacy of CTX112 in adult subjects with refractory **autoimmune disease**, specifically targeting individuals with active **systemic lupus erythematosus (SLE)**, **systemic sclerosis (SSc)**, or **idiopathic inflammatory myopathy (IIM)**. The trial employs a randomized, double-blind, controlled design to ensure unbiased results and reliable data collection. The estimated recruitment start date is October 7, 2025, with the trial expected to conclude by December 1, 2030, indicating a comprehensive study duration of approximately five years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a thorough evaluation of the participant's medical history, current health status, and specific disease characteristics. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor safety, assess treatment efficacy, and collect necessary data for the study's endpoints. The frequency and number of follow-up visits will be determined by the study protocol, ensuring consistent monitoring throughout the trial period.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, final assessments will be conducted to evaluate the long-term effects of the treatment and gather any remaining data required for analysis. The expected length of participant involvement will vary depending on individual response to treatment and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is structured to maintain the highest ethical standards and ensure participant safety throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial may focus solely on the experimental medication without a comparator or placebo group.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial assessment of the investigational product's safety and potential efficacy. The trial is scheduled to commence recruitment on October 7, 2025, with an estimated completion date of December 1, 2030. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often focus on pharmacokinetics, pharmacodynamics, and preliminary efficacy signals. The assessment of efficacy will likely involve the collection and analysis of data at predetermined intervals throughout the trial duration. The methods for measuring and analyzing efficacy will adhere to standard clinical trial protocols, ensuring the reliability and validity of the results. The trial will employ appropriate tools and instruments to capture relevant data, although specific instruments are not mentioned. The results will contribute to the understanding of the investigational product's potential therapeutic benefits.